Crystal structure of the Rho-associated coiled-coil kinase 2 inhibitor belumosudil bound to CK2α.
Acta Crystallogr F Struct Biol Commun
; 78(Pt 10): 348-353, 2022 Oct 01.
Article
in English
| MEDLINE | ID: covidwho-2051824
ABSTRACT
The small molecule belumosudil was initially identified as a selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) and has recently been approved for the treatment of graft-versus-host disease. However, recent studies have shown that many of the phenotypes displayed upon treatment with belumosudil were due to CK2α inhibition. CK2α is in itself a very promising therapeutic target for a range of conditions and has recently been put forward as a potential treatment for COVID-19. Belumosudil presents a promising starting point for the development of future CK2α inhibitors as it provides a safe, potent and orally bioavailable scaffold. Therefore, several of the major hurdles in drug development have already been overcome. Here, the crystal structure of belumosudil bound to the ATP site of CK2α is presented. This crystal structure combined with modelling studies further elucidates how belumosudil could be developed into a selective and potent CK2α or ROCK2 inhibitor.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Casein Kinase II
/
Rho-Associated Kinases
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Acta Crystallogr F Struct Biol Commun
Year:
2022
Document Type:
Article
Affiliation country:
S2053230x22008767
Similar
MEDLINE
...
LILACS
LIS